-61%

est. 2Y upside i

HealthcareSeries A

Rank

#574

Sector

Digital Health

Est. Liquidity

~3Y

Data Quality

Data: Medium

Agebold operates in a promising digital health market for seniors with a strong product and existing partnerships.

Last updated: March 10, 2026

Bull (20%)+350%

Agebold significantly expands its partnerships with Medicare Advantage plans, leveraging proven outcomes to capture a larger share of the $50B Medicare Advantage value-based care market. Revenue accelerates to $30M+ by 2028, justifying a $360M+ valuation (12x revenue) as a leader in senior digital health.

Base (50%)+125%

Agebold continues steady growth, expanding its direct-to-consumer subscriptions and securing a few more regional Medicare Advantage partnerships. Revenue reaches $15M-$20M by 2028, leading to an acquisition or next funding round at a $180M valuation (9-12x revenue).

Bear (30%)-75%

Increased competition from large healthcare incumbents or well-funded digital health players erodes Agebold's market share and pricing power. Growth stalls, and the company struggles to secure new partnerships, leading to a down round or distressed sale at a $20M valuation, significantly impacting common stock value due to liquidation preferences.

Est. time to liquidity~3.0 years

Preference Stack Risk

severe

Investors hold $27M in liquidation preferences, meaning common stock holders may receive little or nothing in an exit at or below this amount.

Dilution Risk

high

As a Series A company, Agebold will likely need at least one or two more significant funding rounds (Series B, C) before an exit, which will lead to further dilution for existing equity holders.

Secondary Liquidity

none

No active secondary market or tender offers are expected at this early stage.

Other — 9 roles

View all 9 open roles at Agebold →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Agebold's data — designed to show you've done your homework.

  • 1

    “Agebold partners with Medicare Advantage plans like UnitedHealthcare's Renew Active. How is the team thinking about defending its market position and value proposition if these large partners decide to develop their own in-house, competing solutions?”

  • 2

    “With current revenue around $5M and a significant TAM, what are the key milestones and growth levers Agebold is focusing on to scale revenue to $20M-$30M over the next two years, particularly in expanding beyond existing partnerships?”

  • 3

    “Given the Series A funding and the estimated time to liquidity, what is the company's philosophy on future equity grants, potential secondary liquidity events, or an IPO timeline for employees?”

Community

Valuation Sentiment

Our model estimates -61% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.